INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
NASDAQ:IART - Nasdaq - US4579852082 - Common Stock - Currency: USD
Overall IART gets a fundamental rating of 4 out of 10. We evaluated IART against 189 industry peers in the Health Care Equipment & Supplies industry. IART has a medium profitability rating, but doesn't score so well on its financial health evaluation. IART has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
IART had a positive operating cash flow in the past year.
IART had positive earnings in 4 of the past 5 years.
IART had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
IART's Return On Assets of -0.16% is fine compared to the rest of the industry. IART outperforms 69.52% of its industry peers.
The Return On Equity of IART (-0.43%) is better than 70.59% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.93%, IART is in the better half of the industry, outperforming 78.07% of the companies in the same industry.
IART had an Average Return On Invested Capital over the past 3 years of 6.75%. This is in line with the industry average of 8.04%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.16% | ||
| ROE | -0.43% | ||
| ROIC | 4.93% |
ROA(3y)3.63%
ROA(5y)3.23%
ROE(3y)8.1%
ROE(5y)7.34%
ROIC(3y)6.75%
ROIC(5y)6.66%
1.3 Margins
IART's Profit Margin has been stable in the last couple of years.
IART's Operating Margin of 11.84% is amongst the best of the industry. IART outperforms 80.21% of its industry peers.
In the last couple of years the Operating Margin of IART has grown nicely.
IART has a Gross Margin (59.29%) which is comparable to the rest of the industry.
IART's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.84% | ||
| PM (TTM) | N/A | ||
| GM | 59.29% |
OM growth 3Y3.4%
OM growth 5Y2.16%
PM growth 3Y-23.36%
PM growth 5Y1.25%
GM growth 3Y-0.76%
GM growth 5Y-0.14%
2. Health
2.1 Basic Checks
IART has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
IART has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of 1.36, we must say that IART is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IART (1.36) is comparable to the rest of the industry.
The Debt to FCF ratio of IART is 47.52, which is on the high side as it means it would take IART, 47.52 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of IART (47.52) is better than 67.38% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that IART is somewhat dependend on debt financing.
IART has a Debt to Equity ratio of 0.79. This is in the lower half of the industry: IART underperforms 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 47.52 | ||
| Altman-Z | 1.36 |
ROIC/WACC0.63
WACC7.81%
2.3 Liquidity
IART has a Current Ratio of 1.20. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.20, IART is not doing good in the industry: 85.03% of the companies in the same industry are doing better.
IART has a Quick Ratio of 1.20. This is a bad value and indicates that IART is not financially healthy enough and could expect problems in meeting its short term obligations.
IART has a worse Quick ratio (0.73) than 89.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
The earnings per share for IART have decreased strongly by -17.42% in the last year.
Measured over the past years, IART shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.35% on average per year.
EPS 1Y (TTM)-17.42%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%8.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.49%
3.2 Future
IART is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.43% yearly.
The Revenue is expected to grow by 6.39% on average over the next years.
EPS Next Y0.16%
EPS Next 2Y5.25%
EPS Next 3Y10.43%
EPS Next 5YN/A
Revenue Next Year6.2%
Revenue Next 2Y5.27%
Revenue Next 3Y6.39%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.32, which indicates a very decent valuation of IART.
IART's Price/Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 97.33% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.43, IART is valued rather cheaply.
With a Price/Forward Earnings ratio of 9.30, the valuation of IART can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 97.33% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.65, IART is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.32 | ||
| Fwd PE | 9.3 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaply inside the industry as 91.44% of the companies are valued more expensively.
74.33% of the companies in the same industry are more expensive than IART, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 48.42 | ||
| EV/EBITDA | 10.56 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of IART may justify a higher PE ratio.
PEG (NY)56.82
PEG (5Y)N/A
EPS Next 2Y5.25%
EPS Next 3Y10.43%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:IART (2/26/2025, 12:49:08 PM)
23.855
-0.86 (-3.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners90.57%
Inst Owner Change-96.2%
Ins Owners3.04%
Ins Owner Change-0.02%
Market Cap1.84B
Analysts52.22
Price Target26.52 (11.17%)
Short Float %5.13%
Short Ratio6.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.22%
Min EPS beat(2)-0.79%
Max EPS beat(2)3.22%
EPS beat(4)1
Avg EPS beat(4)-0.8%
Min EPS beat(4)-3.39%
Max EPS beat(4)3.22%
EPS beat(8)3
Avg EPS beat(8)1.92%
EPS beat(12)5
Avg EPS beat(12)3.13%
EPS beat(16)9
Avg EPS beat(16)6.5%
Revenue beat(2)0
Avg Revenue beat(2)-0.71%
Min Revenue beat(2)-0.77%
Max Revenue beat(2)-0.64%
Revenue beat(4)0
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-2.52%
Max Revenue beat(4)-0.09%
Revenue beat(8)1
Avg Revenue beat(8)-1.08%
Revenue beat(12)2
Avg Revenue beat(12)-0.8%
Revenue beat(16)4
Avg Revenue beat(16)-0.65%
PT rev (1m)0%
PT rev (3m)-7.51%
EPS NQ rev (1m)0.06%
EPS NQ rev (3m)0.06%
EPS NY rev (1m)0%
EPS NY rev (3m)0.22%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.32 | ||
| Fwd PE | 9.3 | ||
| P/S | 1.18 | ||
| P/FCF | 48.42 | ||
| P/OCF | 13.4 | ||
| P/B | 1.21 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.56 |
EPS(TTM)2.56
EY10.73%
EPS(NY)2.56
Fwd EY10.75%
FCF(TTM)0.49
FCFY2.07%
OCF(TTM)1.78
OCFY7.46%
SpS20.28
BVpS19.72
TBVpS-10.43
PEG (NY)56.82
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.16% | ||
| ROE | -0.43% | ||
| ROCE | 5.87% | ||
| ROIC | 4.93% | ||
| ROICexc | 5.41% | ||
| ROICexgc | 28.31% | ||
| OM | 11.84% | ||
| PM (TTM) | N/A | ||
| GM | 59.29% | ||
| FCFM | 2.43% |
ROA(3y)3.63%
ROA(5y)3.23%
ROE(3y)8.1%
ROE(5y)7.34%
ROIC(3y)6.75%
ROIC(5y)6.66%
ROICexc(3y)7.7%
ROICexc(5y)7.53%
ROICexgc(3y)26.08%
ROICexgc(5y)25.66%
ROCE(3y)8.04%
ROCE(5y)7.93%
ROICexcg growth 3Y-0.69%
ROICexcg growth 5Y-4.78%
ROICexc growth 3Y2.49%
ROICexc growth 5Y-0.08%
OM growth 3Y3.4%
OM growth 5Y2.16%
PM growth 3Y-23.36%
PM growth 5Y1.25%
GM growth 3Y-0.76%
GM growth 5Y-0.14%
F-Score4
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 47.52 | ||
| Debt/EBITDA | 3.77 | ||
| Cap/Depr | 73.99% | ||
| Cap/Sales | 6.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.99% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 1.36 |
F-Score4
WACC7.81%
ROIC/WACC0.63
Cap/Depr(3y)44.7%
Cap/Depr(5y)62.4%
Cap/Sales(3y)3.49%
Cap/Sales(5y)4.8%
Profit Quality(3y)128.19%
Profit Quality(5y)136.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.42%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%8.99%
EPS Next Y0.16%
EPS Next 2Y5.25%
EPS Next 3Y10.43%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.49%
Revenue Next Year6.2%
Revenue Next 2Y5.27%
Revenue Next 3Y6.39%
Revenue Next 5YN/A
EBIT growth 1Y-34.31%
EBIT growth 3Y7.5%
EBIT growth 5Y3.1%
EBIT Next Year0.21%
EBIT Next 3Y4.32%
EBIT Next 5YN/A
FCF growth 1Y-79.8%
FCF growth 3Y-19.46%
FCF growth 5Y-9.74%
OCF growth 1Y-44.66%
OCF growth 3Y-11.77%
OCF growth 5Y-6.86%